Skip to main content
. 2024 Feb 27;16(2):152–163. doi: 10.4254/wjh.v16.i2.152

Figure 1.

Figure 1

The pathways contributing to the progression of both liver and muscle dysfunction in metabolic-associated fatty liver disease and sarcopenia. MAFLD: Metabolic-associated fatty liver disease; FFAs: Free fatty acids; IL: Interleukin; TNF-α: Tumor necrosis factor alpha; NASH: Non-alcoholic steatohepatitis; FGF21: Fibroblast growth factor 21; GH: Growth hormone; IGF-1: Insulin-like growth factor 1.